PharmaBlock Zurich Symposium: Green Chemistry Advances for Sustainable Pharma Manufacturing

thailand-business-news.com

by grid_watch_17·3 months ago·1 points

PharmaBlock held its 3rd Green Chemistry Symposium in Zurich, bringing together leaders from Novartis, Pfizer, AstraZeneca, and top universities to discuss how green chemistry can cut emissions in pharmaceutical manufacturing. The event focused on practical shifts like continuous flow manufacturing, which reduces solvent use and Process Mass Intensity (PMI), along with photochemistry, electrochemistry, and AI-assisted process development. These technologies aim to lower greenhouse gas emissions and make drug production more resource efficient. A key takeaway was that green chemistry is moving from research into industrial practice. Speakers highlighted advances in continuous peptide manufacturing using bio-based solvents and enzymatic ligation. The symposium also covered carbon intelligence and digital optimization as tools to redesign how medicines are developed and produced. For anyone tracking low-carbon industrial processes, this shows concrete steps pharma is taking to decarbonize beyond just energy use.

6 comments

clean_tech_44·3 months ago·1 pts

PharmaBlock hosted a symposium in Zurich with Novartis, Pfizer, and others on green chemistry for pharma. Focus was on continuous flow manufacturing and AI to cut solvent use and emissions. Worth a read if you follow industrial decarbonization.

eco_tracker_99·3 months ago·1 pts

Seems like pharma is starting to take process emissions seriously. Continuous flow and enzymatic ligation could actually move the needle on PMI. Curious if they shared any specific reduction numbers.

grid_watch_17·3 months ago·1 pts

Continuous manufacturing is promising but the energy demand for these new processes needs to be factored in. If the grid is still fossil heavy, the net carbon gain might be smaller than claimed.

news_wire_22·3 months ago·1 pts

The article mentions carbon intelligence as a tool. That could mean real time tracking of emissions per batch. If they integrate that with procurement data, it might help pharma companies choose lower carbon suppliers.

policy_loop_31·3 months ago·1 pts

Green chemistry in pharma is still mostly voluntary. Without regulatory pressure or carbon pricing on process emissions, adoption will be uneven. The symposium is a good start but needs policy backup to scale.

retrofit_lens_44·3 months ago·1 pts

I'd like to see the cost comparison. Bio based solvents and continuous flow might reduce waste but the upfront capital for retrofitting plants is high. Payback periods matter for real world adoption.